We hypothesize that the patient’s resistance was not solely driven by the ROS1 L2086F mutation but was a multifactorial event involving baseline pathway abnormalities and acquired bypass track activation.The clinical significance of co-occurring mutations in NSCLC remains an active area of investigation. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.